Although arsenic trioxide (As 2 O 3 ) is an effective therapy in acute promyelocytic leukemia (APL), its use in other malignancies is limited by the toxicity of concentrations required to induce apoptosis in non-APL tumor cells. We looked for agents that would synergize with As 2 O 3 to induce apoptosis in malignant cells, but not in normal cells. We found that trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid), a widely known antioxidant, enhances As 2 O 3 -mediated apoptosis in APL, myeloma and breast cancer cells. Treatment with As 2 O 3 and trolox increased intracellular oxidative stress, as evidenced by HO-1 protein levels, JNK activation, and protein and lipid oxidation. The synergistic effects of trolox may be specific to As 2 O 3 , as trolox does not add to toxicity induced by other chemotherapeutic drugs. We explored the mechanism of this synergy using electron paramagnetic resonance and observed the formation of trolox radicals when trolox was combined with As 2 O 3 , but not with doxorubicin. Importantly, trolox protected non-malignant cells from As 2 O 3 -mediated cytotoxicity. Our data provide the first evidence that trolox may extend the therapeutic spectrum of As 2 O 3 . Furthermore, the combination of As 2 O 3 and trolox shows potential specificity for tumor cells, suggesting it may not increase the toxicity associated with As 2 O 3 monotherapy in vivo.
INTRODUCTION
Arsenic has been used as a therapeutic agent for more than 2,400 years. Until the 1930s, arsenic was used as a treatment for patients with chronic myelogenous leukemia. More recently, the use of arsenic in leukemia has resurfaced after reports from China that arsenic induced a high remission rate in acute promyelocytic leukemia (APL), including those who were resistant to therapy with all-trans retinoic acid 1, 2 .
The activity of arsenic (As 2 O 3 ) in APL is in part related to the disappearance of the PML-RARα fusion protein, the gene product of the chromosomal translocation t(15, 17) characteristic of APL, and the induction of differentiation 3, 4 . As 2 O 3 can also induce apoptosis through a variety of mechanisms, which appear to be independent of PML-RARα degradation 5 . In addition to causing mitochondrial toxicity 6 , impairing microtubule polymerization 7 , and deregulating a number of proteins and enzymes through binding to sulfhydryls groups [8] [9] [10] , considerable evidence suggests that As 2 O 3 induces the accumulation of reactive oxygen species (ROS) and subsequently, induces oxidative stress 11, 12 . Indeed, the intracellular redox status has been shown to be important in predicting whether a cell will respond to arsenic 11, 13 .
Recently it has been shown that As 2 O 3 stimulates apoptosis in additional malignant cells including acute myeloid leukemia, chronic myeloid leukemia, myeloma and various solid tumor cells 14- 17 . However, higher concentrations of As 2 O 3 are required to induce apoptosis in non-APL tumor cells, suggesting that higher, more toxic doses might be needed for clinical efficacy. Clinical trials are currently testing arsenic in the treatment of lymphoma and myeloma 18 , but clear evidence of clinical benefit has, thus far, been largely restricted to patients with APL. Therefore, the sensitization of the resistant tumor cells to As 2 O 3 could expand its therapeutic spectrum.
Different compounds have been reported to enhance As 2 O 3 -mediated apoptosis [19] [20] [21] .
Recently ascorbic acid (AA), a key antioxidant molecule, was reported to augment the toxicity of As 2 O 3 in vitro 22, 23 . However, there is some evidence that the toxicity of ascorbate is due to ascorbic acid-mediated production of hydrogen peroxide, to an extent that varies with the medium used to culture the cells 24 .
Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid) is a hydrophilic vitamin E analogue lacking the phytyl tail, with enhanced antioxidant capacity due to its
For personal use only. on April 14, 2017. by guest www.bloodjournal.org From increased cell permeability. It provides protection against oxidative reactions in aqueous solutions 25 and against cisplatin-induced apoptosis in renal proximal tubular epithelial LLC-PK1 cells 26 . There is also evidence that trolox inhibits DNA damage formation induced by singlet oxygen in human lymphoblast WTK-1 cells 27 and protects red blood cells during photodynamic treatment 28 .
In spite of a large and consistent literature documenting anti-oxidant effects of trolox in several different experimental models, here we report that this compound can enhance 
MATERIALS AND METHODS

Cell lines.
The arsenic trioxide-resistant APL cell line, NB4-M-AsR2 (AsR2), was generated by culturing NB4 cells in the presence of As 2 O 3 at concentrations that were gradually increased over time 13 
Growth Assays
NB4, IM9 and AsR2 cells were seeded at 1x10 5 cells/ml in 24-well plates. Cells were treated with various concentrations of As 2 O 3 or doxorubicin, alone or in combination with 100µM trolox for six days. Viable cells were counted by trypan blue exclusion on day 1, 3 and 6. All cells were maintained at a density lower than 1x10 6 cells/ml through dilution as required, and media +/-treatment was replaced every third day. MCF-7, MDA-231 and T47D were seeded in 24-well plates at a density of 4000 cells/well. The next day, fresh media containing As 2 O 3 +/-trolox was added. On the days indicated, cells were fixed in 10% trichloroacetic acid and subsequently stained with sulforhodamine B (SRB).
Bound SRB was solubilized in 10mM unbuffered Tris and optical density was measured at 570 nm in a microplate reader.
Propidium Iodide Staining.
Quantitation of apoptotic cells was performed as previously described 29 . Cells were treated, washed in buffer (PBS/ 5% FBS/ 0.01 M NaN 3 ) at 4 o C, pelleted, and resuspended in 0.5 ml of hypotonic fluorochrome solution containing 50 µg/ml propidium iodide (PI), 0.1% sodium citrate, and 0.1% Triton X-100. Fluorescence was
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Annexin V staining
Cells were stained with Annexin-V-FITC and Propidium Iodide in binding buffer according to the manufactures recommendations (BD Pharmigen, San Diego, CA). The fluorescent signals of FITC and PI were detected by FL1 at 518 nm and FL2 at 620 nm, respectively, on a FACScan (Becton Dickson, San Jose, CA). Apoptotic cells (Annexin V positive/ PI negative) were quantified using the CellQUEST software.
Western Blotting and immune kinase assays
Cell extracts were washed with cold PBS and resuspended in 0.1 ml lysis buffer (5mM NaH 2 PO 4 , 1mM DTT, 10% glycerol, 1mM PMSF, 10µg/ml each aprotinin and leupeptin, pH 7.4) at 4°C. Extracts were centrifuged at 14,000 rpm at 4°C, and supernatants were transferred to fresh tubes. Protein concentration was determined with the Bio-Rad protein assay (Bio-Rad, Mississauga, Ontario, Canada). To detect HO-1 or PARP, 50µg of protein was added to an equal volume of 2x sample buffer and run on a 10% SDSpolyacrylamide gel. Proteins were transferred to nitrocellulose membranes (Bio-Rad), stained with Ponceau S in 5% acetic acid to ensure equal protein loading, and blocked with 5% milk in PBS containing 0.5% Triton X-100 for 1 hour at room temperature. The membrane was hybridized overnight at 4°C with antibody against PARP (1:1000; Oncogene) or 3 hours with an antibody against HO-1 (1:1000; StressGen). Following three washes with PBS and 0.5% Triton X-100, blots were incubated with a goat antirabbit antibody (1:10,000; PharMingen) for one hour at room temperature. Bands were visualized by enhanced chemiluminescence (Amersham Pharmacia Biotech, Baie d'Urfe, Quebec, Canada). Immunostaining for β-actin was used to confirm equal protein loading.
Immune complex kinase assays for c-jun kinase activity were performed as we have previously described 30 . 33 .
Intracellular reduced GSH levels were assessed enzymatically with glutathione reductase as previously reported 13 .
Peripheral blood mononuclear cell purification and Colony Forming Unit Assay
Peripheral blood mononuclear cells (PBMC) were obtained from two healthy normal donors after obtaining informed consent and were collected into tubes containing 7.2mg K 2 EDTA. The blood was diluted 1:3 in PBS, layered onto an equal volume of FicollPlaque TM PLUS (Amershan Biosciences, Piscataway, NJ) and centrifuged at 1500 rpm for 30 minutes. The mononuclear cell layer was collected and washed twice in PBS.
Methylcellulose media was prepared by combining IMDM, 30% FBS, 1% bovine serum albumin, 10 -4 M 2-mercaptoethanol, 2mM L-glutamine, 0.1U penicillin, 0.1ug/ml streptomycin, granulocyte-macrophage colony-stimulating factor (GM-CSF; 10ng/ml), interleukin-3 (IL-3; 10ng/ml0) and erythropoietin (EPO; 3U/ml). PBMC were seeded in this media at a concentration of 300,000 cells/ml and treated with or without As 2 O 3 , trolox or the combination. Cultures were performed in triplicate in 35mm 2 dishes and incubated at 37 o C in 4% CO 2 . Colonies derived from colony-forming units-erythrocyte (BFU-E) and CFU-GM were counted on day 7 and 13.
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Statistical Analysis.
The significance of data was determined using Prism version 3.0. Analysis of variance followed by Newman-Keuls post-tests were used to determine if cell treatments produced significant changes.
RESULTS
Trolox significantly enhances the inhibitory effects of As 2 O 3 on APL, multiple myeloma and breast cancer cells.
We examined the effects of As 2 O 3 and trolox, both separately and in combination, on the growth of different cell lines. Figure 1A shows that treatment of NB4 cells for six days with 0.5 or 1 µM As 2 O 3 reduced viable cell number by 25%±4.7 and 70%±5.6 of control, respectively. 100µM trolox alone had no effect on cell number at any time point.
However, if the cells were treated with 0.5 or 1 µM As 2 O 3 and 100µM trolox in combination, 57% ±3.5 and 97% ±4.2 reductions of cell number were observed. In all cases, trypan blue positive cells were less than 3%. A difference was also seen between As 2 O 3 and As 2 O 3 +trolox after 72 hours, with 1µM As 2 O 3 decreasing cell number by 30% and the combination by 50% (p<0.001). We next determined whether trolox could sensitize arsenic-resistant cells. We used an NB4-derived, arsenic-resistant subclone (AsR2), which has an IC 50 value roughly 10-times higher than its parental NB4 cell line 13 and the multiple myeloma IM9 cell line, which is also less sensitive to As 2 O 3 than NB4 cells 34 . An enhancing effect of trolox on As 2 O 3 -mediated growth inhibition was observed in both cell lines (Fig 1 B and C) , although trolox did not restore the sensitivity to lower concentrations of As 2 O 3 in the highly resistant AsR2 cell line (data not shown). Some solid tumor cells have been shown to be more resistant to As 2 O 3 than APL cells, so we tested the combined effect of As 2 O 3 and trolox in breast cancer cell lines. As shown in Table 1 , As 2 O 3 -mediated cytotoxicity was enhanced by trolox in all tested cell lines.
Trolox enhances As 2 O 3 -mediated apoptosis in As 2 O 3 sensitive and resistant malignant cells.
To evaluate whether the growth inhibitory effect observed upon combined treatment of We then asked whether trolox could enhance the induction of apoptosis by other cytotoxic agents that induces ROS. The anthracycline doxorubicin has been shown to generate genotoxic stress in a different number of cell types 35, 36 . 1-β-DArabinofuranosylcytosine (AraC) is a nucleoside analog used in the treatment of acute myelogenous leukemia 37, 38 . Etoposide causes single and double-strand DNA breaks when incubated with cells 39, 40 . We examined the possibility that the combination of trolox and doxorubicin, AraC or etoposide might increase cell growth inhibition and apoptosis in NB4 cells. As shown in Figure 2E , these compounds induced apoptosis in a dosedependent manner. However, no additional increase of cellular apoptosis was observed when the cells were co-treated with trolox. Trolox also had no effect on sensitivity to doxorubicin or Ara C in AR2 and IM9 cells (data not shown).
The combination of As 2 O 3 and trolox results in increased cellular oxidative stress.
Oxidative damage has been postulated to be a key mechanism by which arsenic initiates the apoptotic process. Because trolox potentiates As 2 O 3 -induced apoptosis, it is possible that the combination treatment increases cellular oxidative stress. Therefore, we determined whether As 2 O 3 affected various markers for oxidative stress and whether trolox could augment this effect. Heme oxygenase-1 (HO-1), which is the rate-limiting enzyme for heme degradation and has been widely described as a stress responsive protein 41 , was not detected when trolox was used alone ( Figure 3A) . However, the . Therefore, we asked whether the activation of JNK in NB4 cells treated with As 2 O 3 and trolox for 16 hours might play a role in the synergistic effect of these compounds. We used an immune complex assay with GST-c-jun as an exogenous substrate. Figure 5A shows that a 24 hour treatment of NB4 cells with as little as 0.5uM However, when trolox was added to the media, a considerable JNK activation was observed which correlated with apoptotic induction.
As 2 O 3 induces the formation of trolox phenoxyl radicals.
Electron paramagnetic resonance (EPR) is an important tool in experimental studies of systems containing unpaired electrons. We used EPR to directly assay the generation of trolox radicals. As shown in Figure 6B , addition of trolox to reaction mixtures containing As 2 O 3 resulted in the observation of an intense seven-line EPR signal. The g-value (3477.530 G), the relative intensities, and the splittings all confirm the presence of the trolox phenoxyl radical. It's identity is further confirmed by the simulated spectrum ( Figure 6C ), which is based on the published coupling constants for this radical 48 . This signal is not generated by trolox alone ( Figure 6A ) nor in the presence of doxorubicin Figure 6D ) suggesting the requirement of As 2 O 3 and its hydration products for the formation of this radical.
Trolox does not potentiate As 2 O 3 effects in non-malignant cells.
We sought to determine the effects of As 2 O 3 combined with trolox in normal human hematopoietic colony forming cells and mouse embryonic fibroblasts. Normal human PBMCs were isolated, grown in methylcellulose, and treated with As 2 O 3 , trolox or the combination for 2 weeks. Figure 7A shows that 1µM of As 2 O 3 inhibited CFU-E by approximately 62%, but had minimal effect on CFU-GM or BFU-E colony formation.
Treatment with trolox alone did not inhibit colony formation and trolox did not enhance As 2 O 3 -inhibition of CFU-GM, BFU-E or CFU-E. Mouse embryonic fibroblasts were treated with different concentrations of As 2 O 3 for three days, stained with PI and analyzed by flow cytometry. Interestingly, trolox significantly decreased As 2 O 3 -mediated apoptosis at all doses studied ( Figure 7B ).
DISCUSSION
The induction of apoptosis by As 2 O 3 has been linked to the accumulation of free radicals and subsequent induction of oxidative stress. Intracellular oxidative status has been shown to be important for As 2 O 3 sensitivity, and strategies to alter the redox environment may allow normally As 2 O 3 -resistant cells to become susceptible to As 2 O 3 -mediated apoptosis.
In part because of differences in cellular redox environments, As 2 O 3 is less active in most malignant cells than in APL 49 , prompting a search for agents that enhance As 2 O 3 efficacy. One such agent is the widely used antioxidant, ascorbic acid. AA has been shown to potentiate As 2 O 3 -mediated cytotoxicity in HL60 cells, as well as in su-DHL-4 22 , 8226/S and U266 cells 23 . There is some evidence that the time at which AA is administered in relation to exposure to oxidative stress has an impact on AA pro-oxidant capacity in vitro 50 . Co-treatment of Chinese hamster ovary AS52 cells with AA and a radical generating system (RGS) resulted in a significant increase in cell death compared to treatment with RGS alone 50 . However, when AS52 cells were pre-treated for 24 hours with AA and then challenged with RGS, the cells were protected. Ascorbate-generated However, we could not find any differences in the intracellular GSH content upon As 2 O 3 and trolox treatment in any of the cells studied (data not shown) suggesting that, unlike ascorbic acid, the synergy observed between trolox and As 2 O 3 is not due to changes in GSH levels.
To our knowledge, there are only a few reports on the pro-oxidant capacity of trolox.
Synergistic effects between selenite and trolox resulting in enhanced superoxide production and cytotoxicity have been reported. In a mechanism similar to that proposed for As 2 O 3 , cytotoxicity of selenium is believed to involve simultaneous thiol oxidation and superoxide production 59 , and trolox alone had no effect on apoptosis in either the SEK +/+ or SEK -/-cells. Interestingly, trolox protected these non-malignant cells from As 2 O 3 -mediated toxicity although care should be taken when extrapolating these data from murine to human cells.
Consistent with this finding, we found that trolox does not enhance cytotoxicity of As 2 O 3 in colony forming assays using human hematopoietic peripheral blood mononuclear cells.
We show here that the combination of As 2 O 3 and trolox does not increase the As 2 O 3 -mediated reduction in CFU-E, CFU-GM and BFU-E. It has been also found that arsenic damage to supercoiled φX174 DNA and DNA in peripheral human lymphocytes in culture are inhibited by trolox 63 . Therefore, cytotoxic enhancement accruing from trolox exposure may be specific to tumor cells.
In this study, we provide preclinical evidence for the potential efficacy of As 2 O 3 and trolox combination therapy in APL and other malignancies intrinsically less sensitive to As 2 O 3 monotherapy. It is important to note that standard treatment of APL patients with 0.15 mg/kg/d As 2 O 3 yields a maximum concentration of 1 to 2 µM As 2 O 3 in the plasma 64,65 , which is similar to the in vitro doses reported here. Given the low toxicity of trolox and As 2 O 3 and considering the synergy we observed between the two drugs, our results justify the study of this combination in in vivo models of human leukemias and other malignancies.
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